世界の自家細胞治療薬市場：成長、動向、および予測（2020年～2025年）

世界の自家細胞治療薬市場は、予測期間中に15.9％のCAGRで成長する見通しです。同市場の成長に寄与している主な要因は、自己免疫疾患、癌、血液障害などの慢性疾患の発生率の上昇、および慢性疾患に苦しむ人口の増加です。自家細胞治療市場を次のレベルに引き上げる上で重要な役割を果たしている要因の一つは、新しい用途のための進行中の薬剤開発であり、同市場の成長をさらに推進すると予測されています。

当レポートは世界の自家細胞治療薬市場について調査しており、市場機会や動向、成長および阻害要因、療法・用途・素材・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

• 調査成果
• 調査の前提条件
• 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場概況
• 市場成長要因
  • 慢性疾患の発生率の上昇
  • 新しい用途向けの医薬品開発への更なる注力く
• 市場阻害要因
  • 全身性免疫反応の可能性
  • 実施の高コスト、製品および高額の設備投資
• ポーターのファイブフォース分析

第5章 市場セグメンテーション

• 療法別
  • 自家幹細胞療法
  • 自己細胞免疫療法
• 用途別
  • 腫瘍学
  • 筋骨格障害
  • 血液障害
  • 自己免疫疾患
  • その他
• 素材別
  • 骨髄
  • 表皮
  • その他
• エンドユーザー別
  • 病院
  • 研究センター
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • 南米

第6章 競合情勢

• 企業プロファイル
  • Vericel Corporation
  • Pharmicell Co., Inc.
  • Holostem Terapie Avanzate Srl
  • Lineage Cell Therapeutics, Inc.
  • Opexa Therapeutics
  • BrainStorm Cell Therapeutics
  • Sangamo Therapeutics

第7章 市場機会および今後の動向

The Autologous Cell Therapy market studied was anticipated to grow with a CAGR of 15.9%, during the forecast period. The major factors attributing to the growth of the autologous cell therapy market are the rising incidence of chronic diseases such as autoimmune diseases, cancer, blood disorder, and others. A rise in the population suffering from chronic diseases is also propelling the demand for market growth. In 2018, as per the AARDA (American Autoimmune Related Diseases Association) statistics, around 50 million Americans have an autoimmune disease, and this number is expected to rise in the future. As per the CDC (Centers for Disease Control and Prevention) estimates Sickel Cell Disease (SCD) affects around 100,000 Americans annually. And there are few more factors which are playing crucial roles in taking the autologous cell therapy market to the next level, among them one is on-going drug developments for new applications which are expected to further propel the growth of the autologous cell therapy market.

Key Market Trends

Bone Marrow Segment is Expected to Hold the Largest Market Share in the Autologous Cell Therapy Market

• Bone marrow transplant is a technique for replacing damaged and destroyed cells with new stem cells in the bone marrow.
• Bone marrow is the most commonly used for autologous cell therapy as it can benefit individuals with a range of cancer (malignant) and non-cancer (benign) diseases and will drive the market during the forecast period.
• As per the statistics from Globocan 2018, worldwide 18,078,957 individuals have cancer. Asia remains the leading contributor in the rising incidence of cancer with a reported share of 48.4% followed by Europe, North and Latin America, Africa, and Oceania with a share of 23.4%, 13.2% and 7.8%, 5.8%, and 1.4% respectively.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall autologous cell therapy market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cancer, blood disorder, autoimmune diseases, and other diseases and the availability of advanced healthcare infrastructure among the major factors. In North America region, the United States holds the largest market share owing to the factors such as increasing number of population suffering from cancer and other chronic diseases, along with the rising geriatric population and developments related to stem cell therapy and rising demand for biotechnological practices in the country, is anticipated to further drive the demand in this region.

Competitive Landscape

The autologous cell therapy market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Vericel Corporation, Pharmicell Co., Inc., Holostem Terapie Avanzate S.r.l., Lineage Cell Therapeutics, Inc., and Opexa Therapeutics.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Table of Contents

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence of Chronic Diseases
  • 4.2.2 Emphasis Increasingly on Drug Development for New Applications
• 4.3 Market Restraints
  • 4.3.1 Systemic immunological reactions possibility
  • 4.3.2 Expensive practise, product and high capital investment
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Therapy
  • 5.1.1 Autologous Stem Cell Therapy
  • 5.1.2 Autologous Cellular Immunotherapies
• 5.2 By Application
  • 5.2.1 Oncology
  • 5.2.2 Musculoskeletal Disorder
  • 5.2.3 Blood Disorder
  • 5.2.4 Autoimmune Disease
  • 5.2.5 Others
• 5.3 By Source
  • 5.3.1 Bone Marrow
  • 5.3.2 Epidermis
  • 5.3.3 Others
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Research Centers
  • 5.4.3 Others
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 The United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle-East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle-East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Vericel Corporation
  • 6.1.2 Pharmicell Co., Inc.
  • 6.1.3 Holostem Terapie Avanzate S.r.l.
  • 6.1.4 Lineage Cell Therapeutics, Inc.
  • 6.1.5 Opexa Therapeutics
  • 6.1.6 BrainStorm Cell Therapeutics
  • 6.1.7 Sangamo Therapeutics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS